Skip to content
TrialScanner

NCT04806035

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Phase 1TerminatedTGTXLead

Registry record

Lead sponsor
TG Therapeutics, Inc.
Conditions
CLL; SLL; Richter's Transformation; Indolent Lymphoma; Follicular Lymphoma
Primary completion
Jun 12, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04806035 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04806035: Study of TG-1801 Alone or in... | TrialScanner